Page last updated: 2024-08-21

cyclopentane and MODS

cyclopentane has been researched along with MODS in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Altman, JK; Bixby, DL; Blakemore, SJ; DeAngelo, DJ; Dezube, BJ; Erba, HP; Faessel, H; Giles, FJ; Hua, Z; Maris, M; Medeiros, BC; Sedarati, F; Swords, RT	1

Trials

1 trial(s) available for cyclopentane and MODS

Article	Year
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. British journal of haematology, 2015, Volume: 169, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cyclopentanes; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Multiple Organ Failure; Myelodysplastic Syndromes; Pyrimidines; Ubiquitin-Activating Enzymes	2015

Article

Year

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

British journal of haematology, 2015, Volume: 169, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cyclopentanes; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Multiple Organ Failure; Myelodysplastic Syndromes; Pyrimidines; Ubiquitin-Activating Enzymes

2015